Haemonetics (HAE) Stock Breaks Higher With November Test Looming

TLDR Haemonetics stock surged nearly 16% after CSL Plasma announced plans to expand equipment use across U.S. centers. CSL expects to complete the rollout across more than 300 U.S. plasma collection centers by December 2027. BTIG raised its Haemonetics price target to $130, following Citi’s earlier upgrade to Buy. Haemonetics reported $339.38 million in quarterly [...]

The post Haemonetics (HAE) Stock Breaks Higher With November Test Looming appeared first on Blockonomi.